Health Economics Manager
in health
The person who proves a treatment or product is worth paying for: what a UK Health Economics Manager does plus salary bands and career routes.
A Health Economics Manager proves that a treatment, device or product is worth paying for in a real health system, not just in a slide deck. The job is to turn clinical benefit and operational impact into the language that the people holding the budget can act on: cost-effectiveness, budget impact, capacity effects, and the evidence plan that has to stand behind every one of those claims.
The role exists because adoption in health and life sciences is rarely driven by clinicians or users alone. It is driven by the people who carry the financial and clinical risk: NICE and the Scottish Medicines Consortium deciding what the NHS will fund, payers and procurement teams in NHS trusts, finance leads in private hospital groups, and commercial leadership inside pharma, medical devices and diagnostics companies who must defend a price. A Health Economics Manager owns the value story and the evidence strategy that makes a product fundable, scalable, and able to survive scrutiny when the data matures or outcomes vary between sites.
It is more than a modelling job. It is an accountability job. The Health Economics Manager decides what value means for a specific buyer, what evidence is enough, what is too risky to claim, and which trade-offs are acceptable when timelines, data and regulatory expectations collide.
How this role differs across health and life sciences
The settings vary, and so does the bar. In pharma and biotech the work usually orbits formal health technology assessment: cost-utility models, QALYs, and submissions to NICE, the SMC or the All Wales Medicines Strategy Group, where a single committee decision can decide whether a medicine reaches patients. In medical devices and diagnostics the question is often budget impact and pathway redesign rather than a QALY model, because the buyer is an NHS trust weighing capacity and cost, not a national reimbursement body. In contract research organisations (CROs) and HEOR consultancies the same person builds models and dossiers for many clients across many therapy areas. In digital health and health-tech scale-ups the value case has to convince an NHS commissioner who has been pitched a dozen apps that month and wants proof, not a productivity story.
What stays constant is that value must survive clinical scrutiny, budget limits and procurement rules, and it usually has to be expressed in outcomes the vendor does not directly control. Evidence often leans on sensitive health data, messy operational workflows, and real-world variation between sites. The Health Economics Manager has to anticipate what happens when a product moves from a pilot to scaled use, when patient populations differ, and when ideal pathway assumptions meet a ward that is short-staffed.
The consequences are unusually tangible. Overstate the value case and you can trigger failed implementations, a rejected HTA submission, contractual disputes, or lost trust with clinical stakeholders who will remember. That pulls the role closer to decision-making (what can be claimed, what must be tested, what must be caveated) than most economics or analytics roles in other industries.
Core responsibilities
- Define the target use case precisely with product, clinical and commercial teams, because economic value collapses when the indication or pathway is vague.
- Choose comparators, endpoints and patient pathways that are methodologically defensible and feasible given the data and how care is actually delivered.
- Build and quality-assure cost-effectiveness and budget-impact models, and commission or run real-world evidence studies where trial data does not stretch far enough.
- Author or steer HTA submissions and value dossiers for NICE, the SMC, the AWMSG and equivalent bodies, and respond to evidence review group questions.
- Set the evidence standard: decide what is proven, what is expected, and what must be explicitly caveated before anything goes to a payer or procurement team.
- Translate findings into procurement-ready and clinician-sensible narratives without diluting the accuracy.
- Govern external value claims as the product changes, so the case stays stable and defensible when a sophisticated buyer pushes back.
- Manage external partners (HEOR consultancies, academic collaborators, agencies) and align economic assumptions with pricing and contracts.
Skills and competencies in health and life sciences
| Core skill | What it means in health and life sciences | Why it matters |
|---|---|---|
| Health economic modelling | Building and validating cost-effectiveness, cost-utility and budget-impact models in Excel or R, fit for HTA scrutiny | This is the technical core; a model that cannot survive an evidence review group is a liability, not an asset |
| HTA and reimbursement literacy | Knowing how NICE, the SMC and the AWMSG actually assess value, and what payers and NHS procurement need to say yes | Aligns the evidence to the real decision so the work changes a funding outcome rather than sitting in a drawer |
| Economic judgement under uncertainty | Making conservative defensible assumptions when evidence is early, messy or operationally confounded | Reduces over-claiming and builds credibility with buyers who scrutinise every assumption |
| Real-world evidence design | Designing pragmatic studies that fit service constraints, data availability and implementation timelines | Generates evidence that is feasible in live NHS and clinical settings yet still persuasive to decision-makers |
| Stakeholder-grade communication | Turning economic evidence into procurement-ready and clinician-sensible narratives without losing accuracy | Aligns decision-makers on what is proven, what is expected, and what remains unknown |
| Governance and claim control | Setting review standards for external value materials as the product and data change | Keeps the value case stable over time and defensible under challenge |
| Systems and pathway thinking | Understanding patient pathways, bottlenecks and capacity effects rather than isolated feature impact | Captures the real mechanisms behind cost, waiting times and clinical outcomes |
Salary ranges in the UK
Pay in this role tracks how much risk you carry and how close you sit to the funding decision. Scope matters (single product against a portfolio, pilot support against national-scale reimbursement), as does setting: pharma, CROs and consultancies in the London and South East and Cambridge clusters tend to pay more than NHS-facing or regional roles, and a position tied directly to revenue or to a live HTA submission commands more than a support seat. The agency-to-pharma move at mid-career typically lifts total compensation by 30 to 40 percent.
| Experience level | London & South East | Rest of UK | What drives compensation |
|---|---|---|---|
| Junior (analyst / associate) | £36,000–£48,000 | £33,000–£44,000 | Supports modelling, evidence synthesis and value materials under supervision; little accountability for external claims |
| Mid-level (senior analyst / consultant) | £48,000–£70,000 | £45,000–£64,000 | Owns defined workstreams such as a budget-impact model or evaluation plan; pay rises with autonomy and stakeholder exposure |
| Senior (the Manager seat) | £68,000–£92,000 | £62,000–£85,000 | Accountable for the full value story for a product or segment, including assumption governance and cross-functional alignment |
| Lead (senior manager / associate director) | £90,000–£125,000 | £82,000–£115,000 | Leads multiple products or a major evidence programme and becomes the internal standard-setter for claim quality |
| Head / Director | £125,000–£180,000 | £115,000–£165,000 | Portfolio ownership, leadership, external credibility and governance; highest variance with scale and commercial impact |
Sources: Mirko von Hein HEOR Salary and Career Report 2026 (UK total-compensation bands), Jobsite UK (health economics listings, June 2026, average around £95,000 with the bulk of roles between £57,500 and £103,700), plus published market commentary from Hays and Michael Page life-sciences guides. Treat these as a guide; real offers move with employer, setting and specialism.
Beyond base pay, expect a performance bonus, pension and benefits, and in venture-backed health-tech often equity or options. On-call allowances are not typical here, but total compensation still swings on bonus targets, equity value, whether the role is revenue-critical (tied to a reimbursement win, say), and whether it carries people leadership and heavy external stakeholder responsibility.
Career pathways
Common entry points are health economics, outcomes research, public health, epidemiology, statistics, or analyst and consulting roles in pharma, medtech, CROs or healthcare strategy, usually with early exposure to modelling or evidence synthesis. A strong route in is through real-world evaluation work, where you learn first-hand how data quality and implementation constraints shape what you can credibly claim.
Progression comes from widening ownership: first you own the analysis, then the assumptions and the story, then the whole evidence plan and the governance around it. Over time the role broadens from producing economics to setting the standard for what the organisation will claim, how it will prove it, and how it will adapt the value case as the product evolves. Senior progression is earned by being trusted to protect credibility while still enabling growth, especially when commercial pressure pushes for a certainty the data cannot yet support. From there the typical paths are Head of Health Economics, Director of Market Access, or a broader HEOR leadership remit, and lateral moves between pharma, consultancy and device makers are common.
FAQ
Do I need previous HTA submission experience to be credible?
It helps, particularly for pharma and biotech roles built around NICE and SMC work, but it is not always required. What matters most is whether you can build a defensible value case, understand what decision-makers expect, and design evidence plans that fit real deployment constraints. Without submission experience, be ready to show rigour, sound assumption governance, and a clear way of communicating uncertainty. Device, diagnostics and digital health roles often weight budget impact and pathway thinking over formal cost-utility modelling.
How is my performance judged when evidence takes years to mature?
Usually on decision quality and credibility, not raw output. That covers whether stakeholders trust your assumptions, whether your value materials withstand scrutiny, whether evaluation plans are feasible and actually delivered, and whether the organisation avoids over-claiming. Strong performance tends to look like fewer rework cycles and a value story that stays stable as the data evolves.
Will I be expected to be commercial, and what does that mean in practice?
Yes. Commercial here means prioritising the evidence that will unlock adoption and structuring the value case to match buyer incentives, without compromising defensibility. You will influence pricing logic, procurement narratives and roadmap trade-offs while staying clear on what is proven against what is hypothesised. The best Health Economics Managers support growth while actively heading off credibility risk.
Find your next role
If you are looking for your next Health Economics Manager role, whether that is in pharma, a CRO, a device or diagnostics company, the NHS, or a digital health scale-up, search on meeveem and compare opportunities by scope, evidence expectations and ownership.